Serine
CAS 56-45-1
Serine (CAS 56-45-1) is a Phase 3 pharmaceutical compound with 5 bioactivity targets and 3 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29681.585 nM | 32 | - |
| - | Potency | 30906.788888888885 nM | 7 | - |
| - | IC50 | 33306.833333333336 nM | 6 | - |
| - | Ki | 50000 nM | 1 | - |
| Acetylcholinesterase Enzyme |
IC50 | 7.82 | - | Electrophorus electricus |
| Cholinesterase Enzyme |
IC50 | 7.8 | - | Equus caballus |
| Gamma-glutamyltranspeptidase 1 Enzyme |
Ki | 4.3 | - | Rattus norvegicus |
| Asc-type amino acid transporter 1 Unclassified |
IC50 | 5.02 | - | Rattus norvegicus |
| Amino acid transporter Transporter |
IC50 | 4.24 | - | Rattus norvegicus |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Foetal growth restriction | 15 | 69.818 | 10070531 |
| Device related sepsis | 10 | 49.758 | 10069802 |
| Infantile apnoea | 8 | 47.012 | 10077321 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| GPRC6 GPRC6A |
Full agonist | 3.2 pEC50 | 15576628 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| SERINE | 9671 | SU | MTHSPL |
| serine | 9671 | IN | RXNORM |
| L-serine | 9671 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Serine used for in pharmaceutical contexts?
Serine (CAS 56-45-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Serine?
Serine has 3 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Device related sepsis, Infantile apnoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Serine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Serine with EU status "permitted".
What clinical phase is Serine in?
Serine is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Serine?
Serine has 9 bioactivity rows in this page query. Rendered target entries include Acetylcholinesterase, Cholinesterase, Gamma-glutamyltranspeptidase 1, Asc-type amino acid transporter 1, Amino acid transporter.